Rosalinda Termini^1*, Evangelos Terpos, MD, PhD², Albert Pérez, MD^3*, Tomas Jelinek^4*, Nikoletta-Aikaterini Kokkali^5*, Joan Bargay, MD^6*, Fernando Solano Ramos, MD, PhD^7*, Sara Rodríguez, PhD^8*, Cristina Pérez Ruiz^1*, Catarina Maia^1*, Antonio Sacco, RN^9*, Marco Chiarini, MSc^10*, Viviana Giustini, MSc^11*, Jill Corre, PharmD, PhD^12*, Francois Vergez, DVM, PhD^13*, Marc S. Raab, MD^14*, Niels Weinhold, PhD^15*, Aitziber Lopez Lopez^1*, Sonia Garate^1*, Diego Alignani, PhD^1*, Sarvide Sarai^1*, Remco Loos^16*, Antoni Garcia-Guiñon, MD^17*, Maialen Sirvent^18*, José Enrique de la Puerta^19*, Rebeca Iglesias^20*, Maria Casanova, MD^21*, Maria Elena Cabezudo^22*, Valentin Cabañas, MD^23*, Enrique M. Ocio, MD, PhD^24,25, Joaquin Martinez-Lopez, MD^26*, Javier de la Rubia^27*, Artur Paiva^28*, Helena Vitoria^29*, Catarina Geraldes, MD, PhD^28*, Roman Hajek, MD³⁰, Heinz Ludwig, MD³¹, Hartmut Goldschmidt, MD¹⁵, Herve Avet-Loiseau³², Aldo M. Roccaro, MD, PhD³³, Jesús F. San-Miguel³⁴ and Bruno Paiva, PhD^35*

¹Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona, Spain
²National and Kapodistrian University of Athens, School of Medicine, Drosia, Attiki, Greece
³Hospital Universitario Son Espases, Palma, Spain
⁴Faculty of Science, University of Ostrava, Ostrava, Czech Republic
⁵Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
⁶Department of Hematology, Son Llatzer University Hospital/ IdISBa, Palma de Mallorca, Spain
⁷Hospital Ntra Sra del Prado, Talavera De La Reina, Toledo, Spain
⁸Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, PAMPLONA, Spain
⁹Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy
¹⁰Clinical Chemistry Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy
¹¹CREA Laboratory; Clinical Chemistry Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy
¹²Unite de Génomique du Myélome, IUC-T Oncopole, Toulouse, France
¹³Hematology Laboratory, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
¹⁴Max-Eder-Group “Experimental Therapies for Hematologic Malignancies”, German Cancer Research Center, Heidelberg, Germany
¹⁵Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
¹⁶Celgene, Sevilla, Spain
¹⁷Hospital Universitari Arnau de Vilanova, Lleida, Spain
¹⁸Hospital Universitario de Donostia, San Sebastián, Spain
¹⁹Hospital de Galdakao, Vizcaya, Spain
²⁰MD ANDERSON CANCER CENTER, MADRID, Spain
²¹Hematology Department, Hospital Costa del Sol Marbella, Marbella, Spain
²²Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain
²³Hospital Virgen de la Arrixaca de Murcia, Murcia, Spain
²⁴Hematology Department, Hospital Universitario De Salamanca, Santander, Spain
²⁵University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria, Santander, Spain
²⁶Hematology and hemotherapy department, Hospital Universitario 12 De Octubre, Madrid, Spain
²⁷Hematology Department, Internal Medicine, School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain
²⁸Unidade de Gestão Operacional em Citometria, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal, Coimbra, Portugal
²⁹Serviço de Hematologia Clínica, Centro Hospitalar Tondela-Viseu, Viseu, PRT
³⁰University Hospital Ostrava, Ostrava, Czech Republic
³¹Wilhelminenspital, Vienna, Austria
³²Unite de Genomique du Myelome, IUC-T Oncopole, Toulouse, France
³³Department of Hematology, ASST Spedali Civili di Brescia, Brescia, BS, Italy
³⁴Clinical Universidad de Navarra, Pamplona, Spain
³⁵Clinica Universidad De Navarra, Pamplona, Navarra, Spain

Anil Aktas-Samur, PhD^1,2*, Mariateresa Fulciniti, PhD³, Sanika Derebail, MS^4*, Raphael Szalat⁵, Giovanni Parmigiani, PhD^6,7*, Jill Corre, PharmD, PhD^8*, Herve Avet-Loiseau^9,10, Mehmet K. Samur, PhD^11,12 and Nikhil C. Munshi, MD^13,14

¹Department of Data Science, Dana Farber Cancer Institute, Boston, MA
²Harvard School of Public Health, Boston, MA
³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Dana-Farber Cancer Institute, Boston, MA
⁵Boston University School of Medicine, Boston, MA
⁶Harvard T.H. Chan School of Public Health, Boston, MA
⁷Data Science, Dana-Farber Cancer Institute, Boston, MA
⁸Unite de Génomique du Myélome, IUC-T Oncopole, Toulouse, France
⁹Unite de Genomique du Myelome, IUC-T Oncopole, Toulouse, France
¹⁰Universite Paul Sabatier, Toulouse, France
¹¹The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹²Department of Data Science, Dana-Farber Cancer Institute, Harvard TH Chan School of Public Health, Boston, MA
¹³Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹⁴Veterans Administration Boston Healthcare System, West Roxbury, MA

Elina Alaterre, PhD^1*, Laurie Herviou^2*, Hugues De Boussac, PhD^3*, Giorgio Papadopoulos, PhD^2*, Stéphanie Boireau^4*, Nicolas Robert^5*, Guilhem Requirand^5*, Angelique Bruyer^3*, Sara Ovejero-Merino, PhD^2*, Laure Vincent^6*, Anne Marie Martinez^2*, Giacomo Cavalli, PhD^2* and Jerome Moreaux, PhD^2,5,7,8

¹UMR CNRS-UM 9002, Institute of Human Genetics, Montpellier, France
²Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France
³Diag2Tec, Montpellier, France
⁴CHU Montpellier, Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, Montpellier, France
⁵Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, CHU Montpellier, Montpellier, France
⁶CHU de Montpellier / Département d'hématologie clinique, Hôpital Saint-Eloi, Montpellier, France
⁷UFR Médecine, Université Montpellier, Montpellier, France
⁸Institut Universitaire de France, Paris, France

Matteo Claudio Da Via', MD^1,2*, Bachisio Ziccheddu^2,3*, Matteo Dugo^4*, Marta Lionetti, PhD^1,5*, Katia Todoerti, PhD^1,5*, Mattia D'Agostino, MD^6*, Antonino Neri, MD^1,5, Luca Baldini, MD, PhD^1,5*, Paolo Corradini^1,2, Francesco Maura, MD^7,8 and Niccolo Bolli, MD, PhD^1,2*

¹Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
²Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
³Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy
⁴Platform of Integrated Biology, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
⁵BMT Center - Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
⁶Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy
⁷Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁸Weill Cornell Medical College, New York, NY

Mehmet K. Samur, PhD¹, Marco Roncador, MD, MSc^2*, Anil Aktas-Samur, PhD^3,4*, Mariateresa Fulciniti, PhD⁵, Abdul Hamid Bazarbachi, MD^6*, Raphael Szalat⁷, Masood A. Shammas, PhD^8,9*, Adam S Sperling, MD, PhD^10,11, Paul G. Richardson, MD^12,13, Florence Magrangeas^14*, Stephane Minvielle, PhD^14,15*, Anjan Thakurta^16*, Aurore Perrot, MD, PhD^17*, Jill Corre, PharmD, PhD^18*, Philippe Moreau^19*, Kenneth Anderson, MD⁵, Giovanni Parmigiani, PhD^20,21*, Herve Avet-Loiseau²² and Nikhil C. Munshi, MD^23,24

¹Department of Data Science, Dana-Farber Cancer Institute, Harvard TH Chan School of Public Health, Boston, MA
²Dana-Farber Cancer Institute, Brookline, MA
³Department of Data Science, Dana Farber Cancer Institute, Boston, MA
⁴Harvard School of Public Health, Boston, MA
⁵The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Paris, France
⁷Boston University School of Medicine, Boston, MA
⁸The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston
⁹VA Boston Healthcare System, Boston, MA
¹⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
¹¹Harvard Medical School, Boston, MA
¹²The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
¹³Medical Oncology, Harvard Medical School, Boston, MA
¹⁴Université de Nantes, Nantes, France
¹⁵CRCINA, INSERM, CNRS, Angers University and Nantes University, Nantes, France
¹⁶Bristol Myers Squibb, Princeton, NJ
¹⁷Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
¹⁸Unite de Génomique du Myélome, IUC-T Oncopole, Toulouse, France
¹⁹Department of Hematology, University Hospital of Nantes, Nantes, France
²⁰Data Science, Dana-Farber Cancer Institute, Boston, MA
²¹Harvard T.H. Chan School of Public Health, Boston, MA
²²Unite de Genomique du Myelome, IUC-T Oncopole, Toulouse, France
²³Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²⁴Boston VA Healthcare System, West Roxbury, MA

Sara Rodríguez, PhD^1*, Ibai Goicoechea, PhD¹, Katerina Gemenetzi^2*, Cirino Botta, MD, PhD³, Andreas Agathangelidis, PhD^2*, Noemi Puig, MD, PhD^4*, María Teresa Cedena, MD^5*, Alejandro Medina, MD^4*, Rafael Valdés-Mas^6*, Juan José Garcés^1*, José J Pérez^4*, Leire Burgos^1*, María José Calasanz, PhD^1*, Diego Alignani, PhD^1*, Amaia Vilas-Zornoza, PhD^1*, Sarvide Sarai^1*, Felipe Prosper, MD^1*, Jose Angel Martinez-Climent, MD, PhD^1*, Alberto Orfao, MD, PhD⁴, Ramón García-Sanz, MD, PhD^4*, Ana Jiménez Ubieto, MD PhD^7*, Joaquin Martinez Lopez^7*, Juan Jose Lahuerta, MD, PhD^7*, Laura Rosinol, MD, PhD^8*, Joan Bladé, MD, PhD⁸, María-Victoria Mateos, MD, PhD⁴, Anastasia Chatzidimitriou^2*, Jesus F. San-Miguel, MD, PhD¹ and Bruno Paiva, PhD^1*

¹Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona, Spain
²Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece
³Hematology Unit, "Annunziata" Hospital of Cosenza, Cosenza, Italy
⁴Hospital Universitario de Salamanca Hematología. Instituto de investigación biomédica de Salamanca (IBSAL), Salamanca, Spain
⁵Hematology Department, Hospital Universitario 12 de Octubre,, Madrid, Spain
⁶Dreamgenics, Oviedo, ESP
⁷Hospital Universitario 12 de Octubre, Madrid, Spain
⁸Hospital Clínic, Barcelona, Spain